Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory: An Observational Study

NCT07177508 is registered in ClinicalTrials.gov with Nicola Irwin as lead sponsor.

NCT NCT07177508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07177508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory: An Observational Study
Lead sponsor
Nicola Irwin
Phase
Observational
Overall status
Completed
Start date
December 1, 2024
Completion date
July 30, 2025
Enrollment
2,355 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial viral (rsv) infection, respiratory syncytial virus hospitalizations, respiratory syncytial virus prevention